DE2901562A1 - 17-beta-hydroxy-18-methyl-4,15-oestra-di:en-3-one - has progestative, oestrogenic and anti-hypercholesterolaemic activity - Google Patents

17-beta-hydroxy-18-methyl-4,15-oestra-di:en-3-one - has progestative, oestrogenic and anti-hypercholesterolaemic activity

Info

Publication number
DE2901562A1
DE2901562A1 DE19792901562 DE2901562A DE2901562A1 DE 2901562 A1 DE2901562 A1 DE 2901562A1 DE 19792901562 DE19792901562 DE 19792901562 DE 2901562 A DE2901562 A DE 2901562A DE 2901562 A1 DE2901562 A1 DE 2901562A1
Authority
DE
Germany
Prior art keywords
methyl
hydroxy
progestative
oestrogenic
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19792901562
Other languages
German (de)
Inventor
Klaus Dr Kieslich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to DE19792901562 priority Critical patent/DE2901562A1/en
Publication of DE2901562A1 publication Critical patent/DE2901562A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00Preparation of steroids
    • C12P33/12Acting on D ring
    • C12P33/16Acting at 17 position
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00Preparation of steroids
    • C12P33/12Acting on D ring
    • C12P33/16Acting at 17 position
    • C12P33/18Hydroxylating at 17 position

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Steroid Compounds (AREA)

Abstract

17beta-Hydroxy-18-methyl-4, 15-oestradien-3-one (I) has marked progestative, oestrogenic and antihypercholesterolaemic activity, and is prepd. by microbiological redn. of the corresp. 17-oxo deriv. using Sistorema or Trechospora sp.

Description

17ß-Hydroxy-18-methyl-4,15-östradien-3on,17β-Hydroxy-18-methyl-4,15-estradien-3one,

Verfahren zu seiner Herstellung und diese Verbindung enthaltende pharmazeutische Präparate.Process for its preparation and pharmaceutical products containing this compound Preparations.

Die Erfindung betrifft den in den Patentansprüchen gekennzeichneten Gegenstand.The invention relates to that characterized in the claims Object.

Das erfindungsgemäße 17ß-Hydroxy-4, 15-östradien-3-on besitzt eine ausgeprägte progestative, östrogene und antihypercholestereme Wirksamkeit und kann demzufolge als Wirkstoff in pharmazeutischen Präparaten verwendet werden.The 17ß-hydroxy-4, 15-estradien-3-one according to the invention has a pronounced progestative, estrogenic and antihypercholesteremic effectiveness and can can therefore be used as an active ingredient in pharmaceutical preparations.

Das erfindungsgemäße Verfahren zur Herstellung der 17ß-Hydroxy-4,I5-östradien-3-ons wird unter den Bedingungen durchgeführt, die man üblicherweise bei der mikrobiologischen Umsetzung von Steroiden anwendet.The process according to the invention for the preparation of the 17β-hydroxy-4,15-estradien-3-ones is carried out under the conditions that are usually found in microbiological Implementation of steroids.

Unter den üblicherweise verwendeten Kulturbedingungen werden in einem geeigneten Nährmedium unter Belüften, Submerskulturen angezüchtet. Dann setzt man den Kulturen das 18-Methyl-4,15-östradien-3,17-dion (in einem Lösungsmittel gelöst oder vorzugsweise in emulgierter Form) zu und fermentiert bis eine maximale Substratumwandlung erreicht ist.Under the commonly used culture conditions are in a suitable nutrient medium with aeration, submerged cultures. Then you bet the cultures the 18-methyl-4,15-estradiene-3,17-dione (dissolved in a solvent or preferably in emulsified form) and fermented until a maximum substrate conversion is reached.

Geeignete Substratlösungsmittel sind beispielsweise Methanol, Äthanol, Glykolmonomethyläther, Dimethylformamid oder Dimethylsulfoxyd. Die Emulgierung des Substrates kann beispielsweise bewirkt werden, indem man dieses in mikronisierter Form oder in einem mit Wasser mischbaren Lösungsmittel (wie Methanol, Äthanol, Aceton, Glykolmnomethyläther, Dimethylformamid oder Dimethylsulfoxyd) gelöst unter starker Turbulenz in (vorzugsweise entkalktem) Wasser, welches die üblichen Emulgationshilfen enthält, eindüst.Suitable substrate solvents are, for example, methanol, ethanol, Glycol monomethyl ether, dimethylformamide or dimethyl sulfoxide. The emulsification of the Substrates can for example be effected by micronized Form or in a water-miscible solvent (such as methanol, ethanol, acetone, Glykolmnomethyläther, Dimethylformamide or Dimethylsulfoxyd) dissolved under strong Turbulence in (preferably decalcified) water, which the usual emulsification aids contains, inject.

Geeigneten Emulgationshilfen sind nichtiogene Emulgatoren, wie zum Beispiel Äthylenoxyaddukte oder Fettsäureester von Polyglykolen. Als geeignete Emulgatoren seien die handelsüblichen Netzmittel Tegin@, Tweens und Spane beispielsmäßig genannt.Suitable emulsification aids are non-halogenated emulsifiers, such as Example ethyleneoxy adducts or fatty acid esters of polyglycols. As suitable emulsifiers the commercial wetting agents Tegin @, Tweens and Spane are exemplary called.

Die optimale Substratkonzentration, Substratzugabezeit und Fermentationsdauer ist von den angewendeten Fermentationsbedingungen abhängig. Diese Größen müssen, wie dies bei mikrobiologischen Steroidumwandlungen allgemein erforderlich ist, im Einzelfall durch Vorversuche, wie sie dem Fachmann geläufig sind, ermittelt werden.The optimal substrate concentration, substrate addition time and fermentation time depends on the fermentation conditions used. These sizes must as is generally required in microbiological steroid conversions, im Individual cases can be determined by preliminary tests, as they are familiar to the person skilled in the art.

Es ist für den Fachmann überraschend, daß bei dem erfindungsgemäßen Verfahren nur die 17-Ketogruppe reduziert wird, nicht aber die ebenfalls konjugierte Ketogruppe in der 3-Position.It is surprising to the person skilled in the art that in the inventive Only the 17-keto group is reduced in the process, but not the conjugated group Keto group in the 3-position.

Das nachfolgende Beispiel dient zur Erläuterung des erfindungsgemäßen Verfahrens.The following example serves to explain the invention Procedure.

Beispiel 500 ml Erlenmeyerkolben werden mit je 100 ml einer Nährlösung aus 3,0 % Glukose, 1,0 % Corn steep liquor, 0,2 % NaNO31 0,1 % WH2P04, 0,2 °%0 K2HP04, 0,05 O/o MgS04, 0,002 % FeS04 und 0,05 % KC1 oder einer einfacheren Nährlösung aus 2,0 % Glukose und 2,0 % Corn steep beschickt und bei 120 °C 30 Min. im Autoklaven sterilisiert. (pH-Wert vor der Sterilisation 6,0, nach Sterilisation pH 5,7). Die Kolben werden mit der Abschwemmung jeweils einer zwei Wochen alten Schrägagarkultur (Malz- oder Hafermehlagar) von Sistotrema brinkmanii CBS 72769 beimpft und Tage 3 auf einer Rotationsschüttelmaschine mit einer Frequenz von 120 U/Min. bei 23°C geschüttelt. Die gutentwickelten Kulturen werden als Inoculum verwendet zur Beimpfung von 21 Erlenmeyerkolben gefüllte mit 500 ml einer sterilen Nährlösung aus 3,0 % Glukose, 1,0 % Cornsteep liquor, 0,2 % NaNO3, 0,1 % KH2PO4, 0,2 % K2HPO4, 0,05 % MgS04, 0,002 % FeSO4 und 0,05 % KC1.Example 500 ml Erlenmeyer flasks are each filled with 100 ml of a nutrient solution from 3.0% glucose, 1.0% corn steep liquor, 0.2% NaNO31 0.1% WH2P04, 0.2% 0 K2HP04, 0.05% MgS04, 0.002% FeS04 and 0.05% KC1 or a simpler nutrient solution 2.0% glucose and 2.0% corn steep charged and at 120 ° C for 30 minutes in the autoclave sterilized. (pH value before sterilization 6.0, after sterilization pH 5.7). the Flasks are washed away with a two week old agar slant (Malt or oatmeal agar) inoculated from Sistotrema brinkmanii CBS 72769 and days 3 on a rotary shaker at a frequency of 120 rpm. at 23 ° C shaken. The well developed cultures are used as inoculum for inoculation of 21 Erlenmeyer flasks filled with 500 ml of a sterile nutrient solution of 3.0% Glucose, 1.0% Cornsteep liquor, 0.2% NaNO3, 0.1% KH2PO4, 0.2% K2HPO4, 0.05% MgS04, 0.002% FeSO4 and 0.05% KC1.

Die Kolben werden wiederum bei 23 OC und 120 U/Min. geschüttelt und nach einer Anwachsphase von 6 Stunden mit jeweils einer sterilfiltrierten Lösung von 100 mg 18-Methyl-4,t5-östradien-3,17-dion in 1,5 ml Dimethylformamid versetzt. Die Umwandlung wird durch Intervallproben kontrolliert, deren Essigesterextrakte durch DC (Silikagelplatten Merck), System Chloroform/Methanol 9 + 1 analysiert werden.The pistons are turned again at 23 OC and 120 rpm. shaken and after a growth phase of 6 hours with a sterile-filtered solution each time 100 mg of 18-methyl-4, t5-estradiene-3,17-dione in 1.5 ml of dimethylformamide are added. The conversion is controlled by interval samples, their ethyl acetate extracts can be analyzed by TLC (silica gel plates Merck), system chloroform / methanol 9 + 1.

Nach erfolgter Umwandlung (156 bis 356 Stunden Kontaktzeit, analytische Ausbeute 60 % 17ß-Alkohol) werden die Kulturbrühen jeweils zweimal mit je 500 ml Essigester estrahiert und die Extrakte im Vakuum eingedampft. Die Rohprodukte mehrerer Ansätze werden vereinigt und durch präparative Dünnschichtchromatographie an Kieselgel-Fertigplatten (60F/ 254 Merck) unter 5maliger Entwicklung mit dem System Chloroform/Methynol 98 + 2 aufgereinigt. Es werden nach Umkristallisieren aus Isopropyläther erhalten 269 mg 17ß-Hydroxy-18-methyl-4, 15-östradien-3-on, Schmelzpunkt 164/165-166 Unter den gleichen Bedingungen wird die Reduktion durchgeführt mit den Stämmen: Sistotrema brinkmannii CBS 40254 " tr CBS 34153 " " CBS 16060 " II CBS 15438 " VI CBS 34053 " II CBS 40154 " oblongispora CBS 39563 II 1I CBS 39763 Trechospora raduloides CBS 16365After conversion (156 to 356 hours contact time, analytical Yield 60% 17 [beta] alcohol), the culture broths are each twice with 500 ml each Ethyl acetate extracted and the extracts evaporated in vacuo. The raw products of several Approaches are combined and prepared by preparative thin layer chromatography on silica gel plates (60F / 254 Merck) developing 5 times with the system Chloroform / Methynol 98 + 2 cleaned up. After recrystallization from isopropyl ether, 269 are obtained mg of 17β-hydroxy-18-methyl-4, 15-estradien-3-one, melting point 164 / 165-166 Under The reduction is carried out under the same conditions with the strains: Sistotrema brinkmannii CBS 40254 "tr CBS 34153" "CBS 16060" II CBS 15438 "VI CBS 34053 "II CBS 40154" oblongispora CBS 39563 II 1I CBS 39763 Trechospora raduloides CBS 16365

Claims (3)

P a t e n t a n s p r ü c h e 1) 17ß-Hydroxy-18-methyl-4,15-östradien-3on. P a t e n t a n s p r ü c h e 1) 17β-Hydroxy-18-methyl-4,15-estradien-3on. 2) Pharmazeutische Präparate, gekennzeichnet durch den Gehalt von 17ß-Hydroxy-18-methyl-4, 15-östradien-3-on als Wirkstoff. 2) Pharmaceutical preparations, characterized by the content of 17ß-Hydroxy-18-methyl-4, 15-estradien-3-one as an active ingredient. 3) Verfahren zur Herstellung von 17ß-Hydroxy-18-methyl-4,15-östradien-3-on, dadurch gekennzeichnet, daß man 18-Methyl-4,15-östradien-3,17-dion mit einer Pilzkultur der Gattungen Sistotrema oder Trechospora fermentiert. 3) Process for the preparation of 17ß-hydroxy-18-methyl-4,15-estradien-3-one, characterized in that 18-methyl-4,15-estradiene-3,17-dione with a fungal culture of the genera Sistotrema or Trechospora fermented.
DE19792901562 1979-01-12 1979-01-12 17-beta-hydroxy-18-methyl-4,15-oestra-di:en-3-one - has progestative, oestrogenic and anti-hypercholesterolaemic activity Withdrawn DE2901562A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19792901562 DE2901562A1 (en) 1979-01-12 1979-01-12 17-beta-hydroxy-18-methyl-4,15-oestra-di:en-3-one - has progestative, oestrogenic and anti-hypercholesterolaemic activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792901562 DE2901562A1 (en) 1979-01-12 1979-01-12 17-beta-hydroxy-18-methyl-4,15-oestra-di:en-3-one - has progestative, oestrogenic and anti-hypercholesterolaemic activity

Publications (1)

Publication Number Publication Date
DE2901562A1 true DE2901562A1 (en) 1980-12-04

Family

ID=6060689

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19792901562 Withdrawn DE2901562A1 (en) 1979-01-12 1979-01-12 17-beta-hydroxy-18-methyl-4,15-oestra-di:en-3-one - has progestative, oestrogenic and anti-hypercholesterolaemic activity

Country Status (1)

Country Link
DE (1) DE2901562A1 (en)

Similar Documents

Publication Publication Date Title
EP0051762B1 (en) 11-methylene-delta-15 steroids, process for their preparation and pharmaceutical compositions containing them
DE2705917C3 (en) Process for the production of 3 ß, 16 ß -dihydroxy-5-androsten-17-one by microbiological hydrolysis
DE3873200T2 (en) NEW ANDROST-4-EN-3,17-DION DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
CH619268A5 (en)
DE2901562A1 (en) 17-beta-hydroxy-18-methyl-4,15-oestra-di:en-3-one - has progestative, oestrogenic and anti-hypercholesterolaemic activity
DE1904544C3 (en) Process for the microbiological conversion of 3 ß-hydroxy-5,6-epoxy steroids into 6-hydroxy-3-ketoA <· 4 -steroids
DE2636405C2 (en) ?? 1?? 5? -17? -Chlorethinyl and propinyl steroids of the estran series, processes for their preparation and pharmaceutical preparations containing them
EP0014991A1 (en) Microbiological method for the preparation of 7-alpha-hydroxylated steroids
EP0092174B1 (en) 11-beta-chloro-delta-15-steroids, process for their preparation and pharmaceutical compositions containing them
EP0496846B1 (en) Method of preparing 17-oxosteroids
EP0027829A1 (en) Process for the preparation of 9-alpha-hydroxy-4-androstene-3,17-dione
EP0028309B1 (en) Process for the preparation of 11-alpha-hydroxy-20-alpha-hydroxymethyl-1,4-pregnadiene-3-one
EP0261187A1 (en) PROCESS FOR THE PRODUCTION OF 17a$g(a)-HYDROXY-D-HOMO-1,4-PREGNADIENE-3,20-DION
DE1113690B (en) Process for the preparation of 16-methyl-1, 4-pregnadiene-17ª ‡ -ol-3, 20-dione compounds which are substituted in the 11-position by oxygen-containing groups
EP0496854B1 (en) Method for preparation of 20-METHYL-5,7-PREGNADIENE-3$g(b),21-DIOL DERIVATIVES
DE1813997C3 (en)
EP0019162B1 (en) 12-alpha-hydroxy steroids and their preparation
DE1793750C3 (en) Process for the preparation of fluorine compounds of the pregnancy series
DE1230797B (en) Process for 1- and / or 4-dehydration of steroid compounds
DE2047071A1 (en) 11-hydroxylated 1-alpha-2-alpha-methylene steroids - with gestagenic activity
DE2856579A1 (en) 5-Alpha-androstane-3-alpha, 17-beta-diol prodn. - from 4-androstene-di:one or testosterone by fermenting with Rhodotorula glutinis
DE2901563A1 (en) 12-Beta-hydroxy-17-alpha-acyloxy-4-pregnene-3,20-di:ione cpds. - prepd. by microbiological hydroxylation of corresp. unsubstituted steroid(s) with Calonectria decora
DE1793750B2 (en) Process for the preparation of fluorine compounds of the pregnancy series
DE1191371B (en) Process for the preparation of delta 1,4,12-13, 17-seco-androstatriene-3, 11-dione-17-caonic acid compounds and 11-keto-delta 1-dehydrotestolo-lactone compounds
CH339621A (en) Process for the preparation of oxyhalopregnanes

Legal Events

Date Code Title Description
8141 Disposal/no request for examination